Left bundle branch pacing outperformed standard ventricular pacing in heart block
A newer pacemaker strategy moved the heart’s electrical activation closer to its native sequence and, in a large international trial, translated that physiologic advantage into fewer major cardiac events. In people with atrioventricular block, also known as heart block, left bundle branch pacing reduced death, heart failure hospitalization, and pacing-induced cardiomyopathy compared with conventional right ventricular pacing.
The finding matters because heart block is not a rare technical problem at the bedside; it is a rhythm disorder that can slow the pulse enough to cause fatigue, dizziness, fainting, chest pain, and, in severe cases, cardiac arrest. Pacemakers prevent those immediate dangers, but the way a pacemaker delivers electrical impulses also shapes how the ventricles contract over time. A pacing pattern that forces the right ventricle to activate first can create mechanical dyssynchrony, and chronic dyssynchrony can enlarge or weaken the heart muscle.
Left bundle branch pacing was designed to avoid that tradeoff. By delivering the impulse into part of the heart’s intrinsic conduction system, it better preserves coordinated ventricular contraction. That physiologic difference offers a plausible explanation for why the trial separated so clearly on hard clinical outcomes rather than on echo changes alone.
A 59% lower risk on the composite endpoint
The international, multicenter OptimPacing trial enrolled 685 adults and followed them over a five-year period. Participants were randomized in equal numbers to pacemakers using left bundle branch pacing or right ventricular pacing. The average age was 68.4 years, 57.5% were men, and most entered the study with normal left ventricular ejection fraction.
At a median follow-up of three years, the prespecified primary outcome had already diverged enough to meet the trial’s superiority threshold. The composite of death, heart failure hospitalization, or pacing-induced cardiomyopathy occurred in 8.5% of patients assigned to left bundle branch pacing and in 19.2% of those assigned to right ventricular pacing. In relative terms, left bundle branch pacing was associated with a 59% lower risk of the composite endpoint.
One sentence captures the clinical signal cleanly: no participant in the left bundle branch pacing group developed pacing-induced cardiomyopathy.
By contrast, pacing-induced cardiomyopathy developed in 11.7% of the right ventricular pacing group. Heart failure hospitalization also remained numerically lower with the newer approach, occurring in 1.5% versus 2.9% of patients. Those differences suggest the benefit was not driven by a single event type but by broader preservation of ventricular performance.
Why pacing site changes outcomes
In atrioventricular block, the electrical bridge between atria and ventricles is delayed or interrupted, so pacemakers become the substitute conductor. Standard right ventricular pacing solves the bradycardia problem, but it can do so in a way that activates the ventricle out of sequence. When contraction begins in a nonphysiologic pattern day after day, the myocardium can remodel unfavorably, and some patients eventually develop heart failure or pacing-induced cardiomyopathy.
Left bundle branch pacing attempts to avoid that cascade by using the heart’s own conduction network. The pacing impulse reaches the ventricles in a more natural order, which should produce more synchronous squeezing and less long-term mechanical strain. In practical terms, the heart is being stimulated to beat the way it was built to beat.
Jiangang Zou, M.D., Ph.D., said the difference between the two approaches was larger than expected and described left bundle branch pacing as the first choice for patients with heart block who need a pacemaker. That is a strong statement, and the randomized data give it real weight. Still, the numbers should be read in the context of who was studied and how the trial was structured.
Trial design, population, and early stopping
The study ran at 17 centers across mainland China, Hong Kong, the United Kingdom, Poland, and the United States between June 2021 and January 2025. Adults enrolled had second-degree or complete atrioventricular block, or ongoing atrial fibrillation with an average heart rate below 50 beats per minute and related symptoms. Information was gathered before randomization, immediately after implantation, at 6 and 12 months, and then annually.
Major outcomes were independently reviewed by a committee that did not know which pacing strategy each patient received. That blinded adjudication strengthens confidence in the event classification, especially for endpoints such as heart failure hospitalization and pacing-induced cardiomyopathy, where clinical judgment can otherwise introduce noise.
The interim analysis changed the study’s trajectory. An independent monitoring committee reviewed the data after a median of three years and concluded that left bundle branch pacing had crossed the pre-established threshold for superiority. The steering committee then recommended stopping the trial early. Early termination can speed practice-changing decisions, but it can also magnify effect estimates and reduce precision, so the size of the benefit should be interpreted with some caution even as the direction of effect appears consistent.
Who the findings apply to, and who remains unstudied
Most participants had normal pumping function at baseline, which narrows the immediate reach of the results. The trial does not tell clinicians how the same pacing strategy performs in patients who already have reduced left ventricular function at the time of implantation. The investigators also used a single lead type for all left bundle branch pacing procedures, so the findings do not automatically extend to every available pacing tool.
The sample was geographically broad for a device trial and the cohort was large enough to support a meaningful comparison, yet the early stop leaves unanswered questions about durability over longer follow-up. Long-term safety, procedural differences among pacing systems, and cost-effectiveness still need direct study. Those issues matter because device selection is not just about avoiding a slow pulse on day one; it is about preventing years of avoidable ventricular injury after the implant.
For now, the trial places left bundle branch pacing in a stronger position than conventional right ventricular pacing for many patients with heart block and preserved baseline function. It also shifts the discussion from whether physiologic pacing is conceptually better to how broadly it should replace the older standard in routine practice.